About us

Overview

Jobs and careers

People & groups

News

Events

Contact us

PRESS RELEASES (/ABOUT/NEWS/PRESS-RELEASES) / MINI DNA SEQUENCER TESTS TRUE

News overview (/about/news)

News archive (/about/news/archive)

Announcements (/about/news/announcements)

Photos of EMBL-EBI (/about/news/photos)

Mini DNA sequencer tests true

12 Oct 2015 - 16:59

- Public access to Oxford Nanopore's MinION™ miniature sensing device enabled an international consortium to evaluate the technology and provide a standard protocol for its use;
- Preliminary analysis of data generated in five very different laboratories indicates the performance and accuracy of the device is consistently good;
- Data are freely available for re-analysis and innovation in the Nanopore analysis channel on <u>F1000Research</u> (//www.ebi.ac.uk/%20http%3A//bit.ly/1Lvs0nZ).

15 October 2015 – The MinION, a handheld DNA-sequencing device developed by Oxford Nanopore, has been tested and evaluated by an independent, international consortium coordinated by EMBL's European Bioinformatics Institute (EMBL-EBI). The innovative device opens up new possibilities for using sequencing technology in the field, for example in tracking disease outbreaks, testing packaged food or the trafficking of protected species.

The MinION works by detecting individual DNA bases that pass through a nanopore, and unlike existing sequencing technologies, there are few inherent sensing limits on the length of the DNA sequence that it could read at one go. The MinION device was initially made available to thousands of laboratories all over the world, who were inspired to explore the technology and contribute to its development through the MinION Access Programme (MAP).

"The MinION Access Program was a brilliant thing to do. Because the device weighs only 100 grams, Oxford Nanopore could share it easily with more than 1,000 labs worldwide. Some of those people are tinkerers who invented new informatics tools or wet lab techniques that improved MinION performance," says Mark Akeson of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constituting the same cookies, and the lipited tripperstanded by the performance of the performance of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constituting the same cookies, and the lipited tripperstanded by the performance of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constituting the performance of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constituting the performance of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constituting the performance of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the University of California Santa Cruz, a co-inventor of nanopore sequencing, constitution of the

Contact the news team

Oana Stroe

(//www.ebi.ac.uk/about/people/oana-

stroe)

Communications Officer

stroe@ebi.ac.uk

(mailto:stroe@ebi.ac.uk)

+44 (0)1223 494 369

Subscribe to the e-mail newsletter



Get a monthly round-up of the hottest news and features from EMBL, straight to your inbox.

Subscribe

Or stay updated with the RSS feed (EMBL-EBI

Tweets by @emblebi (https://twitter.com/emblebi)

Lagree, dismiss this banner

need to solve critical problems in challenging environments, like tracking Ebola strains during the recent outbreak in West Africa. Another challenging environment is space - the MinION will be the first DNA sequencer tested in space, by NASA on the International Space Station."

"In a few years' time, people who may be several steps removed from basic genomic research, like teachers in a classroom, could be using this device to teach science in new, exciting ways that have never been possible before," adds first author Camilla lp, of Oxford University. "I'm using the MinION in a project with secondary-school students in Oxford because this technology will probably be so much a part of daily life in a few years' time that they take it for granted. The kids who are about to go to university and join the workforce are the ones who will be creating new smartphone apps that use this sensing device for applications we haven't yet imagined."

Five laboratories in the UK, the US, Canada and The Netherlands conducted two sets of ten experiments, for the same E. coli isolate (strain K-12 sub-strain MG1655), using a single, shared protocol. The accuracy and reproducibility of the data were consistent between labs and of good quality. However, there is much work to be done in molecule delivery to flow cells, software protocol clarity and other areas.

The data generated in the study published today represents a snapshot of the MinION's performance in April 2015. Since then, innovation on the MinION has outpaced analysis, with new chips and kits released every 3-6 months. The paper, which includes details of the protocol used and preliminary analysis of the data generated, is available in the Nanopore analysis channel on F1000Research. The data are hosted in the European Nucleotide Archive (ENA).

"Oxford Nanopore has excited the world with the promise of a technology that can be truly disruptive," says David Buck of Oxford University. "When the MinION Access Programme opened it seemed like the largest virtual R&D group ever established in genomics – now the MAP is open to anyone. Working with the MARC team from the start of the MAP has been exciting – we've had the chance to push the technology and gain some traction on understanding what is going on under the hood. We've published the paper in F1000Research before peer review as a baseline for the community, so that everyone can look at the paper and data, go on to do their own analyses share their results and stimulate discussion."

"Nanopore sequencing will open the door for the development of novel tools and applications to analyse the influx of new data," says Rebecca Lawrence, Managing Director of F1000Research. "The Nanopore analysis channel on F1000Research will be a central, open platform on which scientists can publish and discuss new applications and analyse workflows for nanopore sequencing data. People can access and contribute data easily, so that the wider life-science community can realise the full potential of this new technology quickly."

EMBL-EBI has been coordinating the data distribution and analysis for MARC, using the ENA to handle the raw data. "This new device enables fully mobile sequencing with real-time data streaming, which means that with a high-speed Internet connection, the first dataset could arrive 20 minutes after the DNA is loaded," says Guy Cochrane, who leads the ENA at EMBL-EBI. "The ENA is a public resource that extends the reach and usefulness of sequencing, and with new technologies like this we provide the space, flexibility and expertise needed to test it and get it into shape: we were and the limited processing of your personal data in order to management units shape: we were anythelimited processing of your personal data in order to management units shape: we were anythelimited processing of your personal data in order to management units shape: we were carryplace the resultis in the public data in order to shape: www.ebi.ac.uk/data-protection/privacy-notice/embl-ebi-public-website) and Terms of Use (https://www.ebi.ac.uk/about/terms-of-use).

I agree, dismiss this banner

The next phase of analysis is already underway by the consortium, which is exploring ways to reduce the error rate and pushing to see how small the sample and how long the reads can be. •

Source article

lp CLC, et al. (2015). MinION Analysis and Reference Consortium: Phase 1 data release and analysis (http://bit.ly/1LPVGhp). F1000Research. Published online 15 October; DOI: 10.12688/f1000research.7201.1

Editorial in F1000Research at http://bit.lv/1G7ud8Q (http://bit.lv/1G7ud8Q)

Participating organisations

MAP participants are too numerous to list here. Authors on this paper are from the Wellcome Trust Centre for Human Genetics at the University of Oxford, Queens Medical Centre at the University of Nottingham, The Genome Analysis Centre (TGAC), the University of East Anglia and the European Bioinformatics Institute (EMBL-EBI) in the UK; the Malaghan Institute of Medical Research in New Zealand; the University of British Columbia and the Ontario Institute for Cancer Research in Canada; Virginia Commonwealth University, the University of California Santa Cruz, Brown University and Cold Spring Harbor Laboratory in the US; and ZF-screens B.V. in the Netherlands.

Funding and support

This work was funded in part by the Wellcome Trust, Rosetrees Trust, the Biotechnology and Biological Sciences Research Council (BBSRC), the Canadian Institutes of Health Research, the US National Science Foundation, the National Institutes of Health and the National Human Genome Research Institute (NHGRI). Reagents were supplied by Oxford Nanopore Technologies Ltd.

About the MinION Access Programme

The portable MinION device, developed by Oxford Nanopore Technologies Ltd, is a proprietary technology platform for the direct, electronic analysis of single molecules. It works with consumable flow cells that contain the proprietary nanopore sensing apparatus required to perform experiments, and plugs into a PC or laptop that controls the sequencing run. DNA sequencing users generate long reads, analyse data in real-time with a high-speed Internet connection, and use the device in multiple environments. The MinION Access Programme (MAP) is a community-focused technology access programme that started in April 2014 and includes participants in more than 30 countries. Launched as an 'early-access' community the MAP seeks to enable a broad range of people to explore how the MinION may be useful to them in nucleic acid analysis, to contribute to developments in analytical tools and applications and to share their experiences and collaborate. The MAP is now open to any registrant. See tools and publications at http://publications.nanoporetech.com (http://publications.nanoporetech.com)

This website requires cookies, and the limited processing of your personal data in order to the limited processing or the limited process

Lagree, dismiss this banner

F1000Research, launched in 2013, is an open publishing platform for life scientists that offers immediate publication and transparent peer review. F1000Research allows groups to establish their own channels to serve the needs of their community, for example enabling researchers to publish analyses of nanopore sequencing data quickly and easily. This open-science approach facilitates an effective, global, community-wide discussion around the research being produced. The Nanopore analysis channel published on F1000Research features the Phase 1 MARC paper complete with MinION data and a guest editorial. Guest editors of the Nanopore analysis channel are Nick Loman of the University of Birmingham, Matt Loose of the University of Nottingham, Sara Goodwin of Cold Spring Harbour Library and Hans Jansen of ZF-screens B.V.

http://f1000research.com/channels/nanoporeanalysis (http://bit.ly/1Lvs0nZ)

Read more on the EMBL-EBI News page >

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our <u>Privacy Notice</u> (https://www.ebi.ac.uk/data-protection/privacy-notice/embl-ebi-public-website) and Terms of Use (https://www.ebi.ac.uk/about/terms-of-use).

I agree, dismiss this banner